ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1576

IL-23 Promotes Fecal Microbiota Dysbiosis Associated with Susceptibility to Spondyloarthritis and Ileitis in ZAP-70 Mutant SKG Mice

Linda Rehaume1, Nicholas Matigian1, Kate Ormerod2, Alicia Kang1, Richard Linedale1, Olga Zbarskaya1, Kristine Kikly3, Joshua Daly2, Nancy Lachner2, Philip Hugenholtz2, Mark Morrison1, Kim-Anh Lê Cao4 and Ranjeny Thomas1, 1The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia, 2Australian Centre for Ecogenomics, The University of Queensland, Brisbane, Australia, 3Biotechnology Discovery Research, Eli Lilly and Co, Indianapolis, IN, 4School of Mathematics and Statistics, Centre for Systems Genomics, The University of Melbourne, Melbourne, Australia

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: IL-23, inflammatory bowel disease (IBD), microbiome, mouse model and spondylarthropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Identification of disease-associated or protective bacteria may elucidate new biomarkers or probiotic supplements for people suffering from SpA, or for people at-risk of disease development. The colitogenic Prevotella copri was associated with new-onset rheumatoid arthritis, and Prevotella spp. were increased in the cecum of HLA-B27 transgenic rats. In ankylosing spondylitis patients, several bacterial families, including Porphyromonadaceae, were increased. Lactobacillus murinus protects against murine colitis, and ileitis does not occur in germ-free BALB/c ZAP-70W163C-mutant (SKG) mice. Thus, microbes are associated with SpA disease progression and regulation but it is unclear how the microbial community structure differs as a result of genetic susceptibility to SpA, or the impact of additional pro-inflammatory triggers. Since SpA is IL-23- and microbe-dependent in SKG mice, we examined the relationship between IL-23, gut dysbiosis and SpA development in response to microbial β-1,3-glucan (curdlan).

Methods:

Altered Schaedler flora(ASF)-colonized SKG and BALB/c mice were treated one day prior to curdlan, and then weekly, with anti-IL-23 p19-specific mAb or isotype control mAb, or with curdlan or vehicle control. SPF-SKG mice were treated weekly with anti-IL-23 or isotype mAb for 3 weeks, then with curdlan or vehicle control. Fecal samples were collected longitudinally and the microbiota community profiles were analyzed by RT-PCR and sequencing of the 16S rRNA gene using Illumina MiSeq technology. Sequence data was analyzed using QIIME and mixOmics platforms. Arthritis, spondylitis and ileitis were assessed histologically.

Results:

After colonizing germ-free mice with ASF, 4/8 bacterial strains were detected in ASF-SKG and ASF-BALB/c mice: Clostridium sp., Lactobacillus murinus, Mucispirillum schaedleri and Parabacteroides sp. The relative abundance of L. murinus increased in mice treated with curdlan and anti-IL-23 mAb compared with curdlan alone or with isotype mAb. Treatment of naïve SPF-SKG mice with anti-IL-23 mAb significantly altered the fecal microbiota composition relative to isotype mAb treatment for prolonged periods. These shifts persisted after washing out anti-IL-23. The microbiota composition of mice treated with isotype mAb and curdlan was distinct to that of mice treated with anti-IL-23 mAb with curdlan or saline, both of which clustered together regardless of curdlan or saline treatment.

Conclusion:

Interaction of the microbiota with the immune system of SKG mice alters the composition of both a simplified consortium and an unrestricted bacterial community. Curdlan triggers the decline of a gut-protective Lactobacillus species within a simplified consortium. Moreover, IL-23 modifies the host’s support for this gut-protective species. Treatment of SPF-SKG mice with anti-IL-23 mAb not only suppresses SpA development but shifts the fecal microbiota composition and prevents the usual outgrowth of bacteria associated with arthritis and inflammatory bowel disease in response to curdlan. Our results suggest that positive feedback between host IL-23 and dysbiosis predisposes to a host gut environment hostile to gut-protective species and SpA development.


Disclosure: L. Rehaume, None; N. Matigian, None; K. Ormerod, None; A. Kang, None; R. Linedale, None; O. Zbarskaya, None; K. Kikly, Eli-Lilly and Company, 3; J. Daly, None; N. Lachner, None; P. Hugenholtz, None; M. Morrison, None; K. A. Lê Cao, None; R. Thomas, None.

To cite this abstract in AMA style:

Rehaume L, Matigian N, Ormerod K, Kang A, Linedale R, Zbarskaya O, Kikly K, Daly J, Lachner N, Hugenholtz P, Morrison M, Lê Cao KA, Thomas R. IL-23 Promotes Fecal Microbiota Dysbiosis Associated with Susceptibility to Spondyloarthritis and Ileitis in ZAP-70 Mutant SKG Mice [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/il-23-promotes-fecal-microbiota-dysbiosis-associated-with-susceptibility-to-spondyloarthritis-and-ileitis-in-zap-70-mutant-skg-mice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/il-23-promotes-fecal-microbiota-dysbiosis-associated-with-susceptibility-to-spondyloarthritis-and-ileitis-in-zap-70-mutant-skg-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology